GlaxoSmithKline has sent its head of emerging markets and two other top executives to China to lead the drugmaker’s response to an unfolding crisis over alleged bribery and corruption.
Abbas Hussain, GSK’s president of emerging markets, was dispatched by chief executive Sir Andrew Witty, along with the group’s global head of internal audit and a senior legal official. The three will co-operate with Chinese authorities and try to get to the bottom of a scandal that has shaken confidence in GSK’s internal procedures.
On Monday, Chinese police accused the firm of bribing officials and doctors to boost sales and raise the price of its medicines. GSK said it was deeply concerned by the allegations, which it called “shameful”.